Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin.
Hanna RM, Streja E, Kalantar-Zadeh K.
Adv Ther. 2021 Jan;38(1):52-75. doi: 10.1007/s12325-020-01524-6. Epub 2020 Oct 29.
Erythropoiesis-stimulating agent hyporesponsiveness.
Johnson DW, Pollock CA, Macdougall IC.
Nephrology (Carlton). 2007 Aug;12(4):321-30. doi: 10.1111/j.1440-1797.2007.00810.x.
Anaemia in CKD-treatment standard.
Macdougall IC.
Nephrol Dial Transplant. 2024 Apr 26;39(5):770-777. doi: 10.1093/ndt/gfad250.
Role of uremic toxins in erythropoiesis-stimulating agent resistance in chronic kidney disease and dialysis patients.
Nangaku M, Mimura I, Yamaguchi J, Higashijima Y, Wada T, Tanaka T.
J Ren Nutr. 2015 Mar;25(2):160-3. doi: 10.1053/j.jrn.2014.10.011. Epub 2014 Dec 30.
Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient.
Goodkin DA, Zhao J, Cases A, Nangaku M, Karaboyas A.
Am J Nephrol. 2022;53(5):333-342. doi: 10.1159/000523947. Epub 2022 Apr 22.
Erythropoiesis-stimulating agent hyporesponsiveness in end-stage renal disease patients.
Ogawa T, Nitta K.
Contrib Nephrol. 2015;185:76-86. doi: 10.1159/000380972. Epub 2015 May 19.
Association of the erythropoiesis-stimulating agent resistance index and the geriatric nutritional risk index with cardiovascular mortality in maintenance hemodialysis patients.
Yajima T, Yajima K, Takahashi H.
PLoS One. 2021 Jan 15;16(1):e0245625. doi: 10.1371/journal.pone.0245625. eCollection 2021.
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients.
Suttorp MM, Hoekstra T, Rotmans JI, Ott I, Mittelman M, Krediet RT, Dekker FW.
BMC Nephrol. 2013 Sep 25;14:200. doi: 10.1186/1471-2369-14-200.
Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria.
Zhao XN, Liu SX, Wang ZZ, Zhang S, You LL.
Eur J Med Res. 2023 Jul 10;28(1):230. doi: 10.1186/s40001-023-01179-3.
Responsiveness to an erythropoiesis-stimulating agent is correlated with body composition in patients undergoing chronic hemodialysis.
Lee HY, Suh SW, Hwang JH, Shin J.
Front Nutr. 2022 Dec 2;9:1044895. doi: 10.3389/fnut.2022.1044895. eCollection 2022.
